Hepta develops a liquid biopsy platform that uses AI to interpret epigenetic patterns from cell-free DNA in blood to reveal liver biology. This non-invasive technology enables earlier detection and monitoring of metabolic dysfunction-associated steatohepatitis (MASH) in routine clinical care. The platform aims to provide tissue-level insight from a simple blood draw to guide timely treatment decisions for chronic liver diseases.
Funding
$6.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Non-alcoholic steatohepatitis (NASH) diagnosis currently relies on invasive liver biopsies, which are costly, carry risks, and are not suitable for frequent monitoring. This lack of accessible and reliable diagnostic tools hinders early detection and timely intervention, leading to delayed treatment and potentially poorer patient outcomes.
Solution
Hepta Bio is developing a blood-based diagnostic test for NASH that utilizes liquid biopsy technology to analyze methylation patterns in blood samples. This non-invasive approach aims to provide a more accessible and convenient method for detecting and monitoring liver disease. By analyzing specific methylation patterns, the test seeks to improve diagnostic accuracy compared to traditional methods, enabling earlier detection of NASH and facilitating timely intervention. The test is designed to help clinicians detect, monitor, and direct effective treatment for liver disease.
Target Audience
The primary target audience includes hepatologists, gastroenterologists, and primary care physicians who need a reliable and non-invasive tool for diagnosing and monitoring NASH in patients at risk.
Features
- Liquid biopsy technology for non-invasive NASH diagnosis
- Analysis of methylation patterns in blood samples
- Designed for early detection and monitoring of liver disease